hVIVO, a leader in pharmaceutical services, recently expanded its European footprint with the acquisition of two clinical trial units in Germany.
hVIVO plc partners with Inhalon Biopharma, Inc. to test inhaled IN-002 antiviral candidate using RSV Human Challenge Model. Trial set to commence in H2 2026.
hVIVO plc has acquired two Clinical Research Units from CRS, boosting its capabilities in conducting human challenge clinical trials and expanding services.
Explore the innovative world of field studies with FluCamp, revolutionising clinical research by bringing trials closer to real-life scenarios.
hVIVO plc partners with ILiAD Biotechnologies for Phase 3 trial of Bordetella pertussis vaccine, marking a significant milestone in preventing whooping cough.
hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company’s latest achievement here.
hVIVO pioneers infectious disease research with successful hMPV study.
hVIVO plc, a leading CRO specializing in infectious disease testing, announces a £2.7m virology lab contract with a US biotech client.
The importance of diversity in clinical trials cannot be overstated. Addressing gaps in representation is crucial for accurate and inclusive medical research.
hVIVO plc (LON: HVO) has successfully completed a pilot study for its hMPV challenge model, paving the way for new vaccines and antivirals.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
